MedTrace Logo

S0307A, Long-Term Bone Quality in Women With Breast Cancer Enrolled on Clinical Trial SWOG-S0307

NCT00873808 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2013-04-10

No results posted yet for this study

Summary

RATIONALE: Gathering information over time from imaging and laboratory tests of women receiving bisphosphonates for breast cancer may help doctors learn more about long-term bone quality and plan the best treatment. Tetracycline hydrochloride and demeclocycline hydrochloride can mark the new growth of the bone, so it may be seen better under a microscope.

PURPOSE: This clinical trial is studying long-term bone quality in women with breast cancer enrolled on clinical trial SWOG-S0307.

Conditions

Interventions

DRUG

clodronate disodium

DRUG

demeclocycline hydrochloride

DRUG

ibandronate sodium

DRUG

tetracycline hydrochloride

DRUG

zoledronic acid

OTHER

laboratory biomarker analysis

PROCEDURE

adjuvant therapy

PROCEDURE

computed tomography

PROCEDURE

dual x-ray absorptiometry

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • SWOG Cancer Research Network

    lead NETWORK

Principal Investigators

  • Dawn Hershman, MD · Herbert Irving Comprehensive Cancer Center

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2010-02-28
Completion
2010-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00873808 on ClinicalTrials.gov